EORTC protocol 40085 - 75083

Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment.
Trial StatusRecruiting
DatesDate of activation: 23-Apr-13
Data management at EORTCFull
Phase2
Randomized trialYes
TypeAdvanced
Targeted Sample sizeEORTC Groups: 150 - All Groups: 150
Number of steps1
DrugFluorouracil
Cetuximab
Leucovorin
Study StaffMarc Peeters (Study Coordinator) - Universitair Ziekenhuis Antwerpen, Edegem
Murielle Mauer (Statistician) - EORTC Headquarters, Brussels
Edwin Nys (Data Manager) - EORTC Headquarters, Brussels
Carlo Messina (Coordinating Physician) - EORTC Headquarters, Brussels
Nicolas Dif (Project Manager) - EORTC Headquarters, Brussels, nicolas.dif( at )eortc.be, +32 27741043
Christine de Balincourt (Clinical Research Associate) - EORTC Headquarters, Brussels
Type of cancerColorectal
Participating GroupsEORTC Gastrointestinal Tract Cancer Group(Coordinating Group)
EORTC Cancer in Elderly Task Force
Centers authorized by EORTC Universitair Ziekenhuis Antwerpen (Edegem, Belgium) - Inst. 117
Centre Hospitalier Peltzer-La Tourelle (Verviers, Belgium) - Inst. 118
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT01522612
EudraCT2011-002947-83
Protocol documents in PDF
(requires password)
Study documentation
Back to Protocol section